Skip to main content

Question for Department of Health and Social Care

UIN 82390, tabled on 28 August 2020

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of making the drug known as Trikafta or Kaftrio available to people with Cystic Fibrosis through the NHS.

Answered on

14 September 2020

The European Commission formally issued the marketing authorisation for Kaftrio on 21 August. It is therefore now available to be prescribed by National Health Service clinicians to eligible patients through an interim access deal negotiated between NHS England and NHS Improvement and Vertex, the drug manufacturer.